GlassScriptPhysician profile
Maria Leu
NPI 1760772602
$7,189.00
in general payments reported to CMS, 2019-2025
28 companies · $2,245 in 2025
The $2,245 reported for 2025 was more than what 78% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $383 · 2022: $981 · 2023: $1,786 · 2024: $1,794 · 2025: $2,245.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,630 · Education: $195.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,630.09 |
| Education | $194.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,781.33 | 2021-2025 | Airsupra, Tezspire, Fasenra |
| Glaxosmithkline, LLC. | $1,118.62 | 2021-2025 | Trelegy Ellipta, Arexvy, Nucala |
| Mallinckrodt Hospital Products INC. | $609.41 | 2023-2025 | Acthar |
| Boehringer Ingelheim Pharmaceuticals, INC. | $420.26 | 2021-2025 | Ofev, Jascayd |
| Grifols USA, LLC | $393.74 | 2022-2025 | Prolastin-C Liquid, Xembify |
| Regeneron Healthcare Solutions, INC. | $360.23 | 2021-2025 | Dupixent |
| Genzyme Corporation | $313.86 | 2021-2025 | |
| Mylan Specialty L.P. | $276.64 | 2021-2024 | Yupelri |
| Takeda Pharmaceuticals U.S.A., INC. | $263.72 | 2023-2025 | Glassia, Hyqvia |
| Verona Pharma, INC. | $259.72 | 2025 | Ohtuvayre |
| Insmed, INC. | $234.61 | 2022-2025 | Arikayce, Brinsupri |
| Actelion Pharmaceuticals US, INC. | $197.69 | 2022-2024 | Opsumit, Uptravi |
| Inogen, INC. | $170.72 | 2023-2024 | Inogen One G5 Oxygen Concentrator - Bluetooth |
| Merck Sharp & Dohme LLC | $153.56 | 2022-2025 | Zerbaxa, Keytruda, Recarbrio |
| Philips North America LLC | $125.00 | 2022-2024 | (Ak6) Vest Therapy |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| United Therapeutics Corporation | $97.84 | 2025 | Tyvaso |
| Pfizer INC. | $72.23 | 2021-2023 | |
| Teva Pharmaceuticals USA, INC. | $57.25 | 2021 | |
| Baxter Healthcare | $47.74 | 2022-2023 | Hillrom - Life 2000 Ventilation System |
| Genentech USA, INC. | $45.18 | 2021-2022 | |
| Inspire Medical Systems, INC. | $40.87 | 2023-2024 | Inspire |
| Viatris Specialty LLC | $38.67 | 2025 | Yupelri |
| Covis Pharma Gmbh | $30.25 | 2022 | |
| Paratek Pharmaceuticals, INC. | $19.00 | 2022 | |
| Amgen INC. | $16.68 | 2025 | Tezspire |
| Shionogi INC | $16.62 | 2025 | Fetroja |
| Hikma Pharmaceuticals USA | $14.84 | 2024 | Ryaltris |
| Ani Pharmaceuticals, INC. | $12.72 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maria Leu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.